To develop and commercialize novel, first-in-class therapeutics that meaningfully improve the lives of patients with kidney and vascular diseases.
To become a recognized leader in healthcare innovation and a trusted partner to the kidney and vascular communities.
Seek regulatory approval for vonapanitase and commercialize directly in the United States
Partner vonipanitase outside of the United States
Continue development of vonapanitase for additional indications
Build a pipeline of novel therapeutics in kidney and vascular diseases
Timothy Noyes is a veteran biotech leader with deep experience in growing companies and bringing innovative therapies to market. He has served as President, Chief Executive Officer and member of the board of directors at Proteon since 2006. Prior joining Proteon, he was the Chief Operating Officer of Trine Pharmaceuticals from 2002 to 2006 and held several management positions with GelTex Pharmaceuticals prior to its acquisition by Genzyme. After the acquisition, from 2001 to 2002, he held the positions of President, Renal Division and President, GelTex Pharmaceuticals. Earlier in his career, Tim also spent several years at Merck, serving in multiple roles in its hypertension and heart failure group and managed care division. Tim received his A.B. from Harvard College and an M.B.A. from Harvard Business School.
Dr. Steven Burke has extensive drug development experience in both kidney and vascular disease and has been the Senior Vice President and Chief Medical Officer at Proteon since 2006. Before joining Proteon, he worked as Senior Vice President of Medical and Regulatory Affairs and Vice President of Clinical Research at Genzyme for six years. Steven has also held several positions at GelTex Pharmaceuticals, including Vice President of clinical research and medical director at Glaxo. He received an A.B. from Harvard College and an M.D. from
Cornell University Medical College. His medical residency and fellowship were completed at Brigham and Women’s Hospital and he is certified by the American Board of Internal Medicine.
George Eldridge’s financial background and expertise spans multiple industries, including biotechnology and investment banking. At Proteon, George has served as chief financial officer since 2013. From 2009 to 2013, he served as a consultant to companies in the biotech industry, acting as a Chief Financial Officer and providing advisory services. Prior to that, he held the roles of Chief Financial Officer at Targanta Therapeutics, Therion Biologics, Curis (previously Ontogeny) and Boston Life Sciences. George has also worked as an investment banker at Kidder Peabody. He holds a B.A. from Dartmouth College and an M.B.A. from the University of Chicago.
Scott Toner brings a wealth of experience in biopharma sales and marketing, with a particular focus on the commercialization of treatments for patients with kidney disease. Before joining Proteon as Senior Vice President, Marketing in 2015, Scott served as Vice President, Marketing and Sales of OPKO Health’s renal division from 2014 to 2015. From 2013 to 2014, he served as a consultant to companies in the biotechnology industry and from 2011 to 2012 worked as Senior Director, Marketing for Reata Pharmaceuticals. Earlier in his career, Scott spent many years in the domestic and international divisions of Abbott Laboratories, focusing primarily on therapeutics for nephrology and critical care. Scott holds a B.A. from Ithaca College and an M.B.A. from Drexel University.
Daniel Gottlieb brings a wealth of experience in life sciences marketing and corporate development to Proteon. He has served as Vice President of Corporate Development since 2015, prior to which he was Vice President, Marketing and Business Development from 2013 to 2015, Senior Director of Marketing and Business Development from 2010 to 2013 and Director of Marketing and Business Development from 2007 to 2010. Before joining Proteon, Daniel served as the strategic marketing manager of endovascular products at Abbott and held several roles in marketing, business development and corporate venture capital at Guidant Corporation. Daniel has a B.A. from University of Pennsylvania and M.B.A from the Tuck School of Business at Dartmouth College.
Pamela Gustafson joined Proteon in 2006 as the Director of Clinical Research, advanced to Senior Director of Clinical Research in 2012 and became the Vice President of Clinical Research in 2015. She brings a plethora of managerial skills to the leadership team, with over 25 years of experience in the clinical research field. Before joining Proteon, Pamela served as Director of Clinical Operations at Trine Pharmaceuticals. In addition, she has held several managerial positions at AAI International, LeukoSite, PAREXEL International and Alkermes. Pamela earned a B.A. from Wheaton College and an M.P.H. from Boston University. She is also certified as a Project Management Professional.
Brad Hartman comes to Proteon with deep experience scaling biotech companies from early-stage research efforts through product commercialization, creating inclusive, engaging cultures, and developing individuals, teams and organizations. Before joining the Proteon team, Brad served as Vice President, People for Unum Therapeutics from 2016 to 2018, leading all human resource functions during Unum’s rapid growth from research-stage startup to a publicly traded, development stage biotech company. Prior to that, from 2012 to 2016, he co-founded ConnectedSearch, a leading biopharma executive search firm. From 2007 to 2012, Brad held HR roles at both Vertex Pharmaceuticals and Dyax Corporation, where he played a major role building the commercial organizations for three product launches. Brad earned his B.S. in neuroscience from University of Rochester.
Matthew Kowalsky brings a wide range of legal experience to his leadership role at Proteon. He joined Proteon in 2016 as Vice President, Legal and Corporate Secretary. Prior to joining Proteon, he served as Senior Corporate Counsel at Sanofi Genzyme from 2015 to 2016, supporting business development activities and marketed products for rare diseases. Before that, Matt served as Associate General Counsel at Cubist Pharmaceuticals from 2013 to 2015. He has also held similar roles at ARIAD Pharmaceuticals and Lantheus Medical Imaging (formerly Bristol-Myers Squibb Medical Imaging). Matt started his career in the corporate and intellectual property groups of
Choate, Hall & Stewart LLP. He holds a B.A. from University of Notre Dame and a J.D. from Notre Dame Law School. Before attending law school, he served as a surface warfare officer in the U.S. Navy.
John Najim brings a wealth of CMC biopharmaceutical development and cGMP manufacturing experience across multiple biologic expression systems and small molecules. John joined Proteon in 2009, and since 2015 has held the title of Vice President of Manufacturing and Process Development. Previously he served as Senior Director of Manufacturing and Process Development from 2011 to 2014 and as Director of Manufacturing from 2009 to 2011. Prior to joining Proteon, he was the Associate Director of Manufacturing at Dyax Corporation. John has also held a variety of roles at Johnson and Matthew, Genzyme Transgenics and Northeastern University, focused primarily on manufacturing, process development and research development. In these roles John commercialized two biologics license applications and participated in multiple IND applications. He received a B.S. in biochemistry from Merrimack College and M.B.A. from the Graduate School of Business at Bentley University.
Dr. Marco Wong, M.D., Ph.D. joined the Proteon team in 2006 with extensive experience in basic science and clinical research. He led Proteon’s research and development team in Kansas City through various stages of translational research from basic science at the bench, nonclinical, manufacturing at big pharma to clinical research of Proteon’s lead drug candidate. At Proteon, Marco advanced through various roles of increasing responsibility, starting with Physician Scientist/Senior Scientist (from 2006 to 2009) and moving on to Associate Director of Research and Development (from 2009 to 2011) and Medical Director since 2011. He is a co-inventor with numerous patents. At his previous role as a Post-Doctoral Research Associate at the Stowers Institute for Medical Research, Marco conducted genetic and molecular analysis of stem cells and germ cell development. He holds a B.S. from California State University and M.D. and Ph.D. in biochemistry and molecular biology from Wayne State University School of Medicine.